Atossa Therapeutics
| Public | |
| Traded as | NASDAQ: ATOS |
| ISIN | 🆔 |
| Industry | Biotechnology |
| Founded 📆 | 2009 |
| Founder 👔 | Dr. Steven Quay |
| Headquarters 🏙️ | Seattle, Washington |
Area served 🗺️ | |
Key people | Dr. Steven Quay (CEO) |
| Products 📟 | Breast Cancer Pharmaceuticals
The COVID-19 HOPE Program COVID-19 Nasal Spray |
| Members | |
Number of employees | |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
Atossa Therapeutics NASDAQ: ATOS is a Seattle-based clinical-stage biopharmaceutical company.[1][2] Atossa focuses on breast cancer and COVID-19. The company went public and became listed[3] on the NASDAQ stock exchange under the symbol ATOS in 2012.[4]
In 2020, the FDA previously issued a “Safe to Proceed” letter under their expanded access pathway, permitting the use of Atossa’s oral Endoxifen.[5][6] The company is also developing AT-301 for COVID-19 affected patients for treatment at home.[7]
Scientific developments
Atossa concluded its open-label Phase 2 clinical study of oral Endoxifen administered in the “window of opportunity” between diagnosis of breast cancer and surgery based on positive results, allowing acceleration of the Endoxifen program in the United States.[8]
The company announced updated findings following 24 months of an Expanded Access (or “compassionate use”) single-patient study of Endoxifen for breast cancer. And the patient in the study had no cancer recurrence and suffered no side effects. Endoxifen did not cause other safety and tolerability concerns in this patient.[9]
The company received a “Safe to Proceed” letter under the Expanded Access Pathway from the FDA permitting the use of Atossa’s oral Endoxifen as a treatment in an ovarian cancer patient and began treatment.[10]
References
- ↑ Inc, Atossa Therapeutics (2021-05-14). "Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update". GlobeNewswire News Room. Retrieved 2021-05-20.
- ↑ "Atossa Company Information". NASDAQ. Unknown parameter
|url-status=ignored (help) - ↑ "Atossa Therapeutics (ATOS) Stock: Over 17% Increase Explanation". Pulse 2.0. 2021-05-14. Retrieved 2021-05-20.
- ↑ "ATOS Stock Forecast, Price & News (Atossa Therapeutics)". www.marketbeat.com. Retrieved 2021-04-30.
- ↑ "Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA's Expanded Access Pathway". finance.yahoo.com. Retrieved 2021-04-30.
- ↑ "Atossa Therapeutics Inc (ATOS) Stock Moves up Again: Up 55% in a Week – Own Snap". Retrieved 2021-04-30.
- ↑ Hudson, Kate (2021-04-12). "Atossa Therapeutics Inc (NASDAQ:ATOS) Reports Positive Interim Results From Phase 2 Clinical Trial Of Endoxifen In Q4 2020: FDA Permits Expanded Access Of Endoxifen To Treat Ovarian Cancer Patients". BioPharmaJournal. Retrieved 2021-04-30.
- ↑ "atos20181231_10k.htm". www.sec.gov. Retrieved 2021-05-20.
- ↑ Gavins, Felicity (2021-05-03). "Atossa Therapeutics Inc (NASDAQ:ATOS) Commences Treatment Of A Patient With Ovarian Cancer Using Its Proprietary Drug – Endoxifen". BioPharmaJournal. Retrieved 2021-05-20.
- ↑ "Atossa Therapeutics (ATOS) Stock Shouldn't Be Ignored". CNA Finance. 2021-05-17. Retrieved 2021-05-20.
External links
This article "Atossa (Healthcare Company)" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Atossa (Healthcare Company). Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
